Novavax公司由于疫苗销售量减少而削减了2024年的收入预测,导致股票下降7.8%。 Novavax cuts 2024 revenue forecast due to lower vaccine sales, causing shares to drop 7.8%.

Novavax将其2024年的收入预测降至6.5亿美元至7亿美元,由于疫苗销售量减少,从7亿美元降至8亿美元。 Novavax has lowered its 2024 revenue forecast to $650 million to $700 million, down from $700 million to $800 million, due to lower vaccine sales. 这一调整导致其在市场前贸易中的份额下降7.8%,降至8.31美元。 This adjustment caused its shares to drop by 7.8% to $8.31 in pre-market trading. 尽管第三季度收入下降了54.8%,至8450万美元,但净亏损减少到12130万美元,远远高于预期. Despite the revenue falling 54.8% to $84.51 million in the third quarter, the net loss narrowed to $121.30 million, better than expected.